Skip to content
  • Facebook
  • Twitter
This translation is automatically provided by Google; please refer to the original English version for appropriate wording.
Take on Typhoid

Take on Typhoid

  • Home
  • Why Typhoid?
    • Typhoid & Related Salmonelloses
    • Global Research
    • Links & Resources
  • The Issues
    • Vaccines
    • WASH
    • Drug-Resistant Typhoid
    • Treatment
    • Diagnostics
    • Related Issues
  • Resources & Tools
    • Talk About Typhoid
    • Global Policy
    • Country Tools
    • Infographics
    • Fact Sheets
    • TCV Cost-effectiveness
    • Share on Social
  • Blog & News
    • Blog
    • News
    • Publications
    • Newsletter
  • International Conference
    • Past Conferences
    • Conference Travel
  • About Us
    • About the Coalition against Typhoid
    • About the Typhoid Vaccine Acceleration Consortium

IVI-SK’s new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal

Posted on January 12, 2021 by admin
  • Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal
  • This study is a significant milestone in an effort to license Vi-DT TCV

Post navigation

Neno typhoid outbreak
Avoid Any Unnecessary Movement, Rainima Warns On Typhoid

Newsletter Signup

Recent Posts

  • Navigating change as we take on typhoid

  • What does it cost to deliver TCV in Malawi?

  • Analyse de l’eau : de nouvelles méthodes de surveillance pour détecter la typhoïde en Côte d’Ivoire

  • Testing the waters – New surveillance methods for typhoid detection in Côte d’Ivoire

  • Evolving trends in drug resistance of typhoid fever in Bangladesh

cat
685 West Baltimore Street, Room 480
Baltimore, MD 21201-1509
Coalition against Typhoid
2175 K Street, NW, Suite 400
Washington, DC 20037
© 2018. Coalition Against Typhoid. All Rights Reserved.
  • Contact Us
  • Privacy Policy
  • Facebook
  • Twitter
Top